Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding: 2017-2025

Historic Shares Outstanding for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $94.5 million.

  • Crinetics Pharmaceuticals' Shares Outstanding rose 16.96% to $94.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 16.96%. This contributed to the annual value of $92.9 million for FY2024, which is 36.31% up from last year.
  • Crinetics Pharmaceuticals' Shares Outstanding amounted to $94.5 million in Q3 2025, which was up 0.45% from $94.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding registered a high of $94.5 million during Q3 2025, and its lowest value of $4.8 million during Q1 2022.
  • Moreover, its 3-year median value for Shares Outstanding was $79.3 million (2024), whereas its average is $77.9 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Shares Outstanding crashed by 85.52% in 2022, and later soared by 1,029.50% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Quarterly) stood at $47.6 million in 2021, then increased by 13.19% to $53.9 million in 2022, then climbed by 26.54% to $68.2 million in 2023, then surged by 36.31% to $92.9 million in 2024, then increased by 16.96% to $94.5 million in 2025.
  • Its Shares Outstanding was $94.5 million in Q3 2025, compared to $94.1 million in Q2 2025 and $93.5 million in Q1 2025.